Research Medical Center

2316 East Meyer Boulevard
Kansas City, Missouri 64132

816/276-4000

January 24, 1985

Regional Licensing Section
Division of Radiological and Materials Safety
United States Nuclear Regulatory Commission
Region III
799 Roosevelt Road
Glen Ellyn, Ill 60137

Re: Amendment request for NRC License Number 24-18625-01

Gentlemen:

Enclosed please find a request to amend Research Medical Center's NRC Byproduct Materials License Number 24-18625-01. This request is for the following:

1) Group I possession limits of 5 mCi. We wish to utilize a new radioreceptor assay kit for neuroleptic drugs using ^{3}H-spiperone. The kit is called Receptan-N and is manufactured by Wellcome Diagnostics.

   Receptan-N is a radioreceptor method for measuring the dopamine receptor blocking activity of neuroleptic drugs and their active metabolites. It is intended as an aid in the maintenance of effective neuroleptic drug therapy.

   We have also modified our waste disposal procedures reflecting our intended use of ^{3}H-spiperone.

2) Increased Group VI possession limits to 1500 mCi. We have implemented a new stereotactic brain implant procedure using sealed sources of I-125. In addition, we are about to start a bone mineral analysis program. One machine uses 250 mCi of I-125 as its source. Hence, the need for increased possession limits.

3) Possession limits for Gadolinium-153 of 2000 mCi. The Gadolinium is to be used in a spine/femur dual photon bone mineral analysis unit.

4) Changes in our Radiation Safety Procedures for Therapeutic use of Radiopharmaceuticals. Specifically, we are requesting that we be allowed to dispose of urine from I-131 therapy patients in the sanitary sewer system. We are also requesting a modification of our bioassay program following the use of liquid I-131.

8506060686 850517
REG3 LIC30
24-18625-01 PDR

It should be noted that these changes have been previously submitted to the NRC in August of 1984 in our license renewal application. However, due to a significant delay in the review of renewal applications, it was suggested by the NRC that major changes in our program be addressed now through the amendment process.

Thank you for your consideration of this request to amend our license. Should you have any further questions, please do not hesitate to contact me.

Sincerely,

Morton H. Levitt, M.D.
Vice President
Clinical Services

MHL:pf
Enclosure

78208